

# Prospective Assessment of Suicidal Ideation and Behavior: An Internet Survey of Pharmaceutical Sponsor Practices—SUPPLEMENTAL TABLES 1–4

**by ISCTM SUICIDAL IDEATION AND BEHAVIOR ASSESSMENT WORKGROUP; PHILIP B. CHAPPELL, MD; ATUL R. MAHABLESHWARKAR, MD; LARRY D. ALPHS, MD, PhD; MARK E. BANGS, MD; ADAM BUTLER, BA; SARAH J. DuBRAVA, MS; JOHN H. GREIST, MD; WILLIAM R. LENDERKING, PhD; JAMES C. MUNDT, PhD; and MICHELLE STEWART, PhD**

*Dr. Chappell is with Pfizer, Inc., Groton, Connecticut; Dr. Mahableshwarkar is with Takeda Pharmaceutical Company, Deerfield, Illinois; Dr. Alphs is with Janssen Scientific Affairs, Titusville, New Jersey; Dr. Bangs is with Eli Lilly and Company, Indianapolis, Indiana; Mr. Butler is with Bracket Global, Wayne, Pennsylvania; Ms. DuBrava is with Pfizer, Inc., Groton, Connecticut; Dr. Greist is Clinical Adjunct Professor of Psychiatry at University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Dr. Lenderking is with Evidera, Bethesda, Maryland; Dr. Mundt is with Center for Telepsychology, Madison, Wisconsin; and Dr. Stewart is with Pfizer, Groton, Connecticut.*

*Innov Clin Neurosci.* 2014;11(9–10):14–22

**SUPPLEMENTAL TABLE 1.** Factors considered in deciding if a study should include SIB Assessments (N=83 respondents)\*

FACTORS	N	%
Psychiatric or neurologic drug product	79	95.2
CNS active compound	65	78.3
Disease under study	61	73.5
Regulatory announcements and policies	61	73.5
Patient population	59	71.1
Evidence of SIB for other drugs of the same class	45	54.2
CNS effects in Phase 1 trials	40	48.2
Adverse events indicative of SIB	39	47
Capacity of patient population to understand	36	43.4
CNS behavioral effects in animal studies	31	37.3
Type of study (eg, Phase 1 PK or single dose study)	31	37.3
Potential for indirect CNS effects	29	34.9
Background rates of SIB	22	26.5
Micro vs. macro dosing study	9	10.8
Other	4	4.8

\* Respondents were instructed to select all that apply.

SIB: suicidal ideation and behavior; CNS: central nervous system

**SUPPLEMENTAL TABLE 2.** CNS indications including prospective SIB assessments in clinical trials (N=81 respondents)\*

INDICATION	N	%
Schizophrenia	64	79.0
Depression	61	75.3
Bipolar disorder	39	48.1
Alzheimer's disease or other dementia	36	44.4
Anxiety	34	42.0
ADHD	26	32.1
Pain	26	32.1
Mild cognitive impairment	20	24.7
Parkinson's disease	16	19.8
Epilepsy	16	19.8
Autism	15	18.5
Multiple sclerosis	9	11.1
Suicidal ideation and behavior	8	9.9
Alcoholism	7	8.6
Substance abuse	7	8.6
PTSD	7	8.6
Opioid dependence	5	6.2
Stroke	3	3.7
Amyotrophic lateral sclerosis	3	3.7
Traumatic brain injury	1	1.2
Other **	12	14.8

\* For this question, respondents were asked to select from a list of all the CNS disorders studied by their company in clinical trials, which included SIB monitoring.

\*\* "Other" included Down's syndrome (2), migraine (3), binge eating (1), HSDD (hypoactive sexual desire disorder) (1)

CNS: central nervous system; SIB: suicidal ideation and behavior; ADHD: attention deficit hyperactivity disorder; PTSD: posttraumatic stress disorder

**SUPPLEMENTAL TABLE 3.** Non-CNS indications including prospective SIB assessments in clinical trials (N=32 respondents)\*

INDICATION	N	%
Fibromyalgia	13	40.6
Insomnia, other sleep disorders	10	31.3
Smoking cessation	9	28.1
Obesity	8	25.0
HIV	3	9.4
Respiratory allergy/sinusitis	1	3.1
Diabetes	1	3.1
Other**	5	15.6

\* Respondents were instructed to select all that apply.

\*\* "Other" included dermatology (1), renal disease (1), and spasticity (1).

CNS: central nervous system; SIB: suicidal ideation and behavior; HIV: human immunodeficiency virus

**SUPPLEMENTAL TABLE 4.** SIB assessment instruments employed for screening, baseline, and tracking SIB in clinical trials (N=67 respondents)\*

INSTRUMENT	SCREENING		BASELINE		TRACKING	
	n	%	n	%	n	%
Columbia Suicide Severity Rating Scale (C-SSRS)	64	95.5	64	95.5	63	94
IVR version of CSSRS (eCSSRS)	12	17.9	12	17.9	12	17.9
Sheehan Suicide Tracking Scale (S-STSS)	14	20.9	15	22.4	15	22.4
Suicidality module of the Mini Neuropsychiatric Interview	15	22.4	7	10.4	6	9
Concise Health Risk Tracking—Clinician Rating	0	0	1	1.5	1	1.5
Concise Health Risk Tracking—Self Rating	0	0	1	1.5	1	1.5
InterSept Scale for Suicide Thinking (ISST)	7	10.4	7	10.4	7	10.4
InterSept Scale for Suicide Thinking—Plus (ISSTPlus)	4	6	4	6	4	6
Beck Scale for Suicide Ideation	3	4.5	4	6	3	4.5
Suicide Behaviors Questionnaire	2	3	0	0	0	0
Paykel Suicide Scale	0	0	0	0	0	0
Suicide item of the HAMD	18	26.9	18	26.9	17	25.4
Suicide item of the MADRS	20	29.9	21	31.3	21	31.3
Suicide item of the PHQ9	5	7.5	4	6	5	7.5
Suicide item of the IDS/QIDS	5	7.5	6	9	7	10.4
Suicide item of the CDRS	3	4.5	3	4.5	4	6
Don't know	1	1.5	0	0	0	0
Other**	7	10.4	n/a	n/a	n/a	n/a

\* Respondents were instructed to select all that apply.

\*\* Includes screening, baseline, and tracking

SIB: suicidal ideation and behavior; IVR: interactive voice response; HAM-D: Hamilton Rating Scale for Depression; MADRS: Montgomery-Åsberg Depression Rating Scale; PHQ: Patient Health Questionnaire; IDS/QIDS: Inventory for Depressive Symptomatology/Quick Inventory of Depressive Symptomatology; CDRS: Children's Depression Rating Scale